CARA: Cara Therapeutics, Inc. - Summary | Jitta

Cara Therapeutics, Inc.

NASDAQ:CARA

Price
$1.02
Loss Chance
57.9%
1.10JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
1,000 / 1,142
4,733 / 5,003
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (25)
Recent Business Performance (11)
Financial Strength (42)
Return to Shareholders (0)
Competitive Advantage (25)
Jitta Signs
SG&A to SalesDecreasing
Cash Conversion CycleLess than 30 days
Revenue and EarningEarning loss detected in 2022
Operating MarginInconsistent
Recent Business PerformanceEarning decline 24.26% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
1.10
100.00%
2.05
203.83%
2.03
336.26%
Pharmaceuticals
6.89
40.05%
3.31
63.38%
2.90
60.79%
COMPANY DESCRIPTION
Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.